- A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy with TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (3000-03-005/ENGOT-OV44)
To compare the progression-free survival (PFS) of patients with Stage III or IV ovarian cancer treated with platinum-based therapy, TSR-042, and niraparib to standard-of-care (SOC) platinum-based therapy.
- Phase 3 Randomized Trial Comparing Overall Survival After Photon versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB Non-Small Cell Lung Cancer (NSCLC)
To compare the good and bad effects in terms of patient life span after these 2 different types of radiation therapy (photon versus proton) in combination with FDA-approved chemotherapy for lung cancer. This study will allow the researchers to know whether the proton therapy approach is better, the same, or worse then the usual photon approach in terms of survival.
- A Phase 3, randomized, double-blind, adaptive, placebo/paclitaxel-controlled study of AVB-S6-500 in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer. (GOG 3059)
To evaluate the effect of AVB-S6-500 plus Paclitaxel versus placebo and Paclitaxel on progression-free survival based on response evaluation criteria in solid tumors criteria, in subjects with platinum-resistant ovarian cancer.
- A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination with Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent. (GOG-3053)
The treatment of participants with newly diagnosed, high-risk EC following surgery with curative intent.
- A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (EMERALD-2)
To assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab monotherapy or placebo as adjuvant therapy. This study will be conducted in patients with HCC who are at high risk of recurrence after curative hepatic resection or ablation. 888 patients will be enrolled globally.
- Phase 2 Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer
To test whether bupropion, a medication that is approved for depression and smoking cessation, can improve sexual desire compared to placebo
- MIRASOL: A randomized, open label, phase 3 study of Mirvetuximab Soravtansine vs. Investigator’s choice of chemotherapy in Platinum-Resistant Advance High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with high folate receptor-alpha expression. (GOG 3045)
To compare the progression-free survival of patients randomized to Mirvetuximab Soravtansine vs. investigator’s choice of chemotherapy.
- Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC)
To obtain information on the safety & effectiveness of the NovoTTF-100M (study device) in patients with brain metastases (tumors) from non-small cell lung cancer.
- Prospective Research Assessments in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
To examine how multiple myeloma is treated by doctors all over the world, how people respond to these treatments, & the economic impact of these treatments
- 14.0012 - Evaluation Tracking Project: A Prospective Chart Review of Patients Treated with Radiation Therapy
To collect & analyze information on people with similar cancer diagnosis. The effectiveness of procedures & treatments, the usefulness of various tests, and the incidence of short or long-term side effects will be evaluated. The ultimate goal is to improve effectiveness of treatments & procedures & limit side effects & late complications for patients.
- 16.0001 - Pragmatic Phase III Randomized Trial of Proton versus Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial
To compare 2 types of standard care radiation treatment: photon and proton, to find out which type is best for treating non-metastatic breast cancer.
- A randomized, Open-label, Phase 3 Trial of Tisotumab Vedotin vs Investigator’s choice chemotherapy in second or third-line recurrent of metastatic cervical cancer. (GOG-3057)
Demonstrate improvement in clinical efficacy of tisotumab vedotin compared to chemotherapy in participants with second or third-line cervical cancer
- 15.0007 - Phase 3 Randomized, Double-blind, Placebo Controlled, Multicenter Study to Compare the Efficacy & Safety of Lenalidomide Plus R-CHOP Chemotherapy (R2-CHOP) versus Placebo Plus R-CHOP Chemotherapy in Subjects with Previously Untreated Activated B-Cell (ABC) Type Diffuse Large B-Cell Lymphoma (DLBCL). (The “ROBUST” Study)
To evaluate the effectiveness & safety of lenalidomide, rituximab, cyclophosphamide, doxorubicin, vincristine, & prednisone (R2-CHOP) chemotherapy versus placebo, rituximab, cyclophosphamide, doxorubicin, vincristine, & prednisone (placebo-R-CHOP) chemotherapy in people who have previously untreated ABC type DLBCL
- A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma
To compare the efficacy of TACE with Duravalumab + Bevacizumab, TACE with Duravalumab alone and TACE only.
- A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-paclitaxel versus Placebo plus Carboplatin-paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer
Determine the efficacy and safety of dostarlimab plus carboplatin-paclitaxel versus placebo plus carboplatin-paclitaxel in patients with recurrent or primary advanced (Stage III or IV) endometrial cancer.
- 17.0008 - A Pivotal, Double-blind, Randomized, Placebo-controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients being Treated with Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck
To test the safety & efficacy of SGX942 in any resulting oral mucositis in patients with squamous cell carcinoma of the head and neck who will also receive treatment with chemotherapy and radiation therapy
- A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 & 6 Inhibitor, in Combination with Fulvestrant Compared to Chemotherapy in Women with HR Positive, HER2 Negative Metastatic Breast Cancer with Visceral Metastases
To compare the efficacy of abemaciclib in combination with fulvestrant to that of physician’s choice of chemotherapy in patients with HR+, HER2- metastatic breast cancer with at least 1 site of visceral metastases & at least 1 line of prior Endocrine Therapy.
- A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix. (GOG-3030)
To determine whether the addition of atezolizumab to chemotherapy and bevacizumab improves overall survival compared to chemotherapy plus bevacizumab in patients with metastatic persistent or recurrent carcinoma of the cervix
- A Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of topically-applied AG013 for the attenuation of oral mucositis in subjects with cancers of the head and neck receiving concomitant chemoradiation therapy.
To determine the effectiveness as well as safety & tolerability of AG013 in altering the onset, course & severity of oral mucositis compared to placebo (a mouth rinse which looks exactly the same as AG013 but which dose not contain AG013) when administered 3 times each day.
- informCLL: A Disease Registry for Patients with Chronic Lymphocytic Leukemia
To describe current treatment patterns in the real-world setting among CLL patients who are beginning treatment with approved oral kinase inhibitors or other approved anti-CLL therapies/regimens as well as any association with patient characteristics, healthcare resource utilization, clinical outcomes, & patient-reported outcomes.
- Observational Study of Patients with Polycythemia Vera in U.S. Clinical Practices (REVEAL)
To describe the clinical burden, healthcare resource utilization, complications, practice patterns, and therapy strategies in patients treated for PV in academic & community clinical practices within the United States.
- 20.0004 - The COVID-19 and Cancer Consortium (CCC19) Registry
To collect granular information on cancer patients infected with COVID-19.
- An intermediate access protocol for selumetinib for treatment of neurofibromatosis type 1 with inoperable, progressive/symptomatic plexiform neurofibromas
To provide access to selumetinib to people with neurofibromatosis type 1 (NF1) with plexiform neurofibromas that cannot be operated on.
- A Prospective Comparative Study of Outcomes with Proton and Photon Radiation in Prostate Cancer (COMPPARE)
To determine if prostate cancer patients treated with proton therapy, as compared to IMRT, experience:
Improved quality of life
Reduced toxicity
Non-inferior or even superior cancer control
To determine if Hypofractionated proton therapy is non-inferior to standard fractionated proton therapy in patient-reported outcomes & physician-reported toxicity.